SEARCH:   Advanced

Blood, 15 December 2007, Vol. 110, No. 13, pp. 4614-4617. Prepublished online as a Blood First Edition Paper on September 19, 2007; DOI 10.1182/blood-2007-04-082990. This Article Full Text (PDF) All Versions of this Article: blood-2007-04-082990v1 110/13/4614    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Olavarria, E. Articles by Craddock, C. F Search for Related Content PubMed PubMed Citation Articles by Olavarria, E. Articles by Craddock, C. F Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 23, 2007 Accepted September 15, 2007 Post-transplant imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced intensity allografts for chronic myeloid leukemia Eduardo Olavarria, Shamyla Siddique, Michael J Griffiths, Sharon Avery, Jenny L Byrne, Karen P Piper, Anne L Lennard, Lalit Pallan, Julie M Arrazi, Jolanta B Perz, Derville O'Shea, John M Goldman, Jane F Apperley, and Charles F Craddock* Department of Haematology, Imperial College, Hammersmith Hospital, London, United Kingdom CRUK Institute for Cancer Studies, University of Birmingham, Birmingham, United Kingdom West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital, Birmingham, United Kingdom Department of Haematology, Nottingham City Hospital, Nottingham, United Kingdom Department of Haematology, Newcastle Royal Infirmary, Newcastle, United Kingdom Department of Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom * Corresponding author; email: charles.craddock{at}uhb.nhs.uk. Disease relapse is a major cause of treatment failure after reduced intensity allografts and whilst donor lymphocyte infusions (DLI) can be effective salvage therapy they are associated with severe GVHD when administered early post-transplant. We have therefore examined whether imatinib mesylate can delay relapse and postpone the requirement for DLI in 22 patients with chronic myeloid leukemia (CML) allografted using a reduced intensity regimen. Imatinib was commenced on day+35 and continued until one year post-transplant. Post-transplant imatinib was well-tolerated and abolished the risk of relapse during this period. 21 patients completed 11 months imatinib therapy of whom 15 subsequently relapsed and received DLI. 10 patients to date have achieved molecular remission after DLI. Adjunctive targeted therapy allows the kinetics of disease relapse after a reduced intensity allograft to be manipulated and represents a novel strategy by which outcome may be improved in patients transplanted for CML and other leukemias CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: N. B. Heaney, M. Copland, K. Stewart, J. Godden, A. N. Parker, I. G. McQuaker, G. M. Smith, C. Crawley, P. Shepherd, and T. L. Holyoake Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia Blood, May 15, 2008; 111(10): 5252 - 5255. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020